SIMABS

Agoralaan, Abis Abis /

3590 Diepenbeek

BE

SIMABS

Foundation date

22AUG2019

Sector

#Biotechnology / R&D Services

Subsector

Therapeutic areas

SIMABS is a start-up biotechnology venture that wants to develop a new bio-manufacturing platform to provide cost effective therapeutic monoclonal antibodies at small scale to biopharmaceutical companies.

Upcoming events

Latest news

  • SeptiCyte® RAPID receives 510(k) clearance by US FDA

    Wednesday December 1st 2021

  • QbD and Inovigate launch Health to Market, a contract commercialization organization in life sciences

    Wednesday December 1st 2021

  • Dimitrios Mantzilas joins Precirix as Chief Technology Officer

    Wednesday December 1st 2021